IPC partners with fellow nonprofits in dermatology and psoriasis to share knowledge, collaborate on research, and advocate for better patient care worldwide.
The International Federation of Psoriasis Associations (IFPA) is a nonprofit organization that unites national and regional psoriasis associations worldwide. Since their founding in 1971, they have worked to address the international psoriasis community’s challenges. IFPA campaigns on behalf of all people with psoriasis and psoriatic arthritis, with goals to empower members, improve patients’ living conditions, raise awareness, and collaborate with fellow stakeholders.
The IPC and IFPA are currently working together on:
– Global Psoriasis Atlas (GPA)
– Recategorization of disease severity
– Telemedicine
– Diverse Skin Tones
The National Psoriasis Foundation (NPF) is a nonprofit organization in the United States dedicated to finding a cure for psoriasis and psoriatic arthritis. It serves as a resource for individuals affected by these conditions, providing support, education, and advocacy. The NPF conducts research, raises awareness, and works to improve access to effective treatments and healthcare for people living with psoriasis and psoriatic arthritis.
Founded in 2003, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) is an international nonprofit consortium dedicated to advancing research, education, and patient care in psoriasis and psoriatic arthritis. GRAPPA brings together more than 1,000 rheumatologists, dermatologists, radiologists, epidemiologists, geneticists, patient research partners, and other experts from around the world. Through treatment recommendations, outcome measures, educational programs, and collaborative research initiatives, GRAPPA works to improve the understanding, diagnosis, and management of psoriatic disease globally. Approximately 75% of its members are based outside North America, reflecting its international reach.
The International Eczema Council (IEC) is a global nonprofit organization led by dermatology and allergy experts in atopic dermatitis, founded in 2014 and dedicated to improving patient care by promoting research, education, and best practices in the management of atopic dermatitis worldwide.
The IEC is governed by a Board of Directors comprised primarily of leading international experts in atopic dermatitis, including a patient representative. Today, more than 180 Councilors and Associates from over 35 countries across six regions contribute their expertise to support the IEC’s research, educational programs, and global initiatives.
Founded in 1935, the International League of Dermatological Societies (ILDS) has been promoting skin health worldwide for over 80 years. Its forerunner began in 1889 as the first of many World Congresses of Dermatology (WCD). Today, the ILDS represents dermatology at the highest level, with over 180 Member Societies from more than 80 countries, representing over 200,000 dermatologists. ILDS works closely with partners worldwide, including the World Health Organization (WHO), with whom it maintains official relations, to improve skin health for all people.
The Pan-American League of Associations for Rheumatology (PANLAR), founded in 1944, brings together national rheumatology societies, healthcare professionals, and patient groups from across North, Central, and South America. Its mission is to improve the lives of people living with rheumatic diseases throughout the Americas by advancing research, education, and clinical care, while promoting early diagnosis, access to treatment, and equitable standards of care across the region. PANLAR supports scientific exchange, guideline development, educational initiatives, and international congresses that advance the understanding and management of rheumatic diseases.
Founded in Buenos Aires, Argentina, in July 2008, SOLAPSO was established by dermatologists committed to advancing the understanding, diagnosis, and treatment of psoriasis in Latin America. Formally established as a civil association in November 2008, SOLAPSO promotes regional awareness through events across multiple countries and supports scientific publications focused on psoriasis in Latin America.
IPC Councilor Helen Young provides commentary on a study identifying skin-derived myeloid precursors and CD200+ fibroblasts as key drivers of psoriatic disease spread from the skin to joints, highlighting the CD200–CD200R1 axis as a promising therapeutic target.
IPC Fellow Dr. Yemsrach Abawaji shares her firsthand perspective on the barriers to psoriasis diagnosis and treatment in Ethiopia and opportunities to improve care.
Did you miss the IPC symposium at the 83rd Society for Investigative Dermatology (SID) Annual Meeting? Select session videos are now available. The Arc of Disease Control in Psoriasis: Early Interception – Deep Pathway Blockade – Treatment Failure covered early intervention strategies, treatment selection, immune pathway targeting, PsA prevention, clinical escape, and real-world cases that inform long-term psoriasis care.
Depression affects approximately 20% of patients with psoriasis, five times the rate seen in the general population. IPC Jr. Councilor Mio Nakamura, MD, MS, FAAD, walks through the bidirectional relationship between psoriasis and depression, the shared inflammatory pathways driving both conditions, and practical guidance on screening and incorporating multidisciplinary mental health support into psoriasis management.
